Implementation Strategy: What Does a Successful Surgical Instrument Management System Implementation Look Like?

Technology plays a central role in every aspect of medical advancement — even in the surgical asset management field.

On an episode of ConCensis host, Tyler Kern was joined by Theresa Cole, a Sterile Processing Manager at Northern Nevada Sierra Hospital, and Jason Blake, a project manager with Censis Technologies – the company behind CensiTrac, a system being used to manage all things surgical instrument management.

When health centers and facilities look to adopt a new system, there are several key things that they look for. But for Cole, her main goal was to work with a software that facilitated patient tracking and was easy to use.

“The most important thing is being able to track to the patients … kind of a thorough implementation to be able to track through the process. We’ve used CensiTrac in the past so as a system I was familiar with, I was very comfortable and confident using it at this facility,” said Cole.

The CensiTrac system was the most significant factor for Cole’s interest in her management job. The Censis software was going to be used at Northern Nevada Sierra, which piqued Cole’s interest. “CensiTrac was in place … because there’s very extensive modules to be able to track paperless, track to the patient, track the instrumentation … it was a very comprehensive system so that was a selling feature for sure,” stated Cole.

Having a support team in the surgical asset management field is also important. The Censis implementation team assists hospital staff on how to use the system, ensuring proper and safe security measures, and getting people all on the same page for a smooth process.

Early preparation stands to be the main factor in effectively implementing sterile processing and what has to be prioritized.

“The main thing is their data – what is their information going to look like,” said Blake.

For sterile processing, these things include items like count sheets and instrumentation. Blake stated, “that is core training for a tracking system to ensure that you have the right data in place. All their trays, the tray names — anything that has to do with that first is a really big thing.”

He added that coordinating with information technology personnel and understanding the hardware should be emphasized in surgical asset management because oftentimes, switching from one system to another or implementing into a totally new system might come with trial and error since every facility has its own needs.

Interested in learning more about Censis Technologies’ surgical asset management platform? Visit Censis.com.

To access additional podcasts, visit the ConCensis Podcast Show featured on MarketScale.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More